Centre for Cancer Therapeutics
The Vanderhyden lab is located in the Centre for Cancer Therapeutics in the Ottawa Hospital Regional Cancer Centre. When it was first constructed in 1995, the scientists designed this research space based on an open concept design and this has facilitated much interaction and collaboration. There are currently 12 scientists and clinician-scientists with labs in the Centre for Cancer Therapeutics and a description of our colleagues and their areas of research can be found here.
Cellular and Molecular Medicine
The majority of graduate students working in the area of ovarian cancer in Ottawa are registered in the Cellular and Molecular Medicine graduate program in the Faculty of Medicine at the University of Ottawa. This program offers a range of courses in physiology, pathology, developmental biology, reproduction and cancer biology. Our colleagues in the Department of Cellular and Molecular Medicine work on a broad array of research topics.
Division of Gynecologic Oncology
The long-term goal of any basic research program is the translation of the major findings into an action that has clinical application, such as more effective treatments or strategies for more reliable or earlier detection. In Ottawa, there are strong interactions among the scientists and clinicians to ensure that the research has clinical relevance and that pathways to clinical application are frequently explored. The Division of Gynecologic Oncology is home to four gynecologic oncologists, a pathologist and basic scientists, all with interests in various aspects of ovarian cancer diagnosis, research and treatment.
Ovarian Cancer Labs
In addition to the Vanderhyden lab, there are several other basic research labs in Ottawa with interests in ovarian cancer. Dr. Jim Dimitroulakos is exploring the mechanisms by which targeted therapeutics and statins inhibit ovarian cancer cell proliferation and survival. Dr. Jonathan Lee has demonstrated that the protein elongation factor eEF1A2 is a putative oncogene in ovarian cancer and may have prognostic significance. Chemoresistance is a major problem in the clinical management of women with ovarian cancer, and Dr. Benjamin Tsang has published extensively on the molecular pathways that play a role in mediating this chemoresistance, including those involving AKT, XIAP and p53. The most recent recruit to the Ovarian Cancer Research Program is Dr. Johanne Weberpals, a gynecologic oncologist. Dr. Weberpals investigates the mechanisms by which deficiencies in BRCA1 expression promote tumour progression in women with sporadic ovarian cancer.
Members of the Ovarian Cancer Research Program, August 2007